ES2247527T3 - Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona. - Google Patents
Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona.Info
- Publication number
- ES2247527T3 ES2247527T3 ES03715221T ES03715221T ES2247527T3 ES 2247527 T3 ES2247527 T3 ES 2247527T3 ES 03715221 T ES03715221 T ES 03715221T ES 03715221 T ES03715221 T ES 03715221T ES 2247527 T3 ES2247527 T3 ES 2247527T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- cycloalkyl
- independently selected
- triaril
- triona
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de fórmula I en la que dicho anillo X es un anillo heterocíclico de 5-7 miembros seleccionado del grupo constituido por (Ver fórmulas) en la que cada línea a trazos representa un doble enlace opcional; en la que cada uno de R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 y R 13 se selecciona independientemente del grupo constituido por hidrógeno, alquilo (C1-C4), alquenilo (C1-C4), alquinilo (C1-C4), arilo (C6-C10), heteroarilo (C1-C10), cicloalquilo (C3-C7) y heterociclilo (C1-C10); en la que cada uno de dichos R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 y R 13 alquilo (C1-C4) puede estar opcionalmente sustituido por uno a tres sustituyentes seleccionados independientemente del grupo constituido por F, Cl, Br, CN, OH, -(C=O)-OH, -(C=O)-O-alquil (C1-C4), -(C=O)-NH2, -(C=O)-NH-alquilo (C1-C4), -(C=O)-N[(alquil (C1-C4)]2, perfluoroalquilo (C1-C4), perfluoroalcoxi (C1-C4), alcoxi (C1-C4), -NH2, -NO2, alquil (C1-C4)-NH-, [alquil(C1-C4)]2-N- y cicloalquil (C3-C7) oxi. en la que cada uno de dichos R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 y R 13 arilo (C6-C10), heteroarilo (C1-C10), cicloalquilo (C3-C7) y heterociclilo (C1-C10) pueden estar opcionalmente sustituidos sobre cualquiera de los átomos de carbono del anillo que pueda soportar un sustituyente adicional con de uno a tres sustituyentes por anillo seleccionados independientemente entre F, Cl, Br, CN, OH, -(C=O)-OH, -(C=O)-O-alquilo (C1-C4), -(C=O)-NH2, -(C=O)-NH-alquilo (C1-C4), -(C=O)-N[(alquilo (C1-C4)]2, perfluoroalquilo (C1-C4), perfluoroalcoxi (C1-C4), alcoxi (C1-C4), -NH2, -NO2, alquil (C1-C4)-NH-, [alquil (C1-C4)]2-N- y cicloalquil (C3-C7) oxi;
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37615702P | 2002-04-26 | 2002-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2247527T3 true ES2247527T3 (es) | 2006-03-01 |
Family
ID=29270770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES03715221T Expired - Lifetime ES2247527T3 (es) | 2002-04-26 | 2003-04-15 | Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona. |
Country Status (17)
Country | Link |
---|---|
US (1) | US6916807B2 (es) |
EP (1) | EP1501834B1 (es) |
JP (1) | JP2005527598A (es) |
AR (1) | AR039661A1 (es) |
AT (1) | ATE304015T1 (es) |
AU (1) | AU2003219410A1 (es) |
BR (1) | BR0309281A (es) |
CA (1) | CA2483075A1 (es) |
DE (1) | DE60301574T2 (es) |
ES (1) | ES2247527T3 (es) |
GT (1) | GT200300097A (es) |
MX (1) | MXPA04008563A (es) |
PA (1) | PA8572201A1 (es) |
PE (1) | PE20040466A1 (es) |
TW (1) | TW200306833A (es) |
UY (1) | UY27774A1 (es) |
WO (1) | WO2003091259A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003223012A1 (en) | 2002-04-26 | 2003-11-10 | Pfizer Products Inc. | Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors |
WO2003091259A1 (en) | 2002-04-26 | 2003-11-06 | Pfizer Products Inc. | Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
NI200300045A (es) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
JP2005529895A (ja) * | 2002-04-26 | 2005-10-06 | ファイザー・プロダクツ・インク | N置換へテロアリールオキシ−アリール−スピロ−ピリミジン−2,4,6−トリオンメタロプロテイナーゼ阻害剤 |
EP1750862B1 (en) | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
EP2125750B1 (en) * | 2007-02-26 | 2014-05-21 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
ATE554078T1 (de) * | 2007-07-26 | 2012-05-15 | Vitae Pharmaceuticals Inc | Synthese von 11-beta-hydroxysteroid-dehydrogenase-1-hemmern |
AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
WO2009075835A1 (en) | 2007-12-11 | 2009-06-18 | Vitae Pharmaceutical, Inc | CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1 |
TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
US8592409B2 (en) * | 2008-01-24 | 2013-11-26 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
JP5734666B2 (ja) * | 2008-02-11 | 2015-06-17 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の1,3−オキサアゼパン−2−オン及び1,3−ジアゼパン−2−オン阻害剤 |
JP5730021B2 (ja) * | 2008-02-15 | 2015-06-03 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の阻害剤としてのシクロアルキルラクタム誘導体 |
JP5538356B2 (ja) * | 2008-03-18 | 2014-07-02 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害剤 |
CA2723032A1 (en) * | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
AR071236A1 (es) | 2008-05-01 | 2010-06-02 | Vitae Pharmaceuticals Inc | Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1 |
EP2291370B1 (en) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
AR071609A1 (es) * | 2008-05-01 | 2010-06-30 | Vitae Pharmaceuticals Inc | Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1 |
WO2010010157A2 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 |
CA2730499A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2393807B1 (en) | 2009-02-04 | 2013-08-14 | Boehringer Ingelheim International GmbH | Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1 |
TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
MA33216B1 (fr) | 2009-04-30 | 2012-04-02 | Boehringer Ingelheim Int | Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1 |
US20100331320A1 (en) * | 2009-04-30 | 2010-12-30 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2440537A1 (en) | 2009-06-11 | 2012-04-18 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
US8883778B2 (en) | 2009-07-01 | 2014-11-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 |
EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
EP2585444B1 (en) | 2010-06-25 | 2014-10-22 | Boehringer Ingelheim International GmbH | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
WO2012059416A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
EP3886853A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | DIARYLHYDANTOI COMPOUNDS AND METHODS OF USE THEREOF |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US96803A (en) * | 1869-11-16 | Improvement in machine for bending thills | ||
US132822A (en) * | 1872-11-05 | Improvement in thrashing-machines | ||
US6057A (en) * | 1849-01-23 | Guard or stripper for stirring-machines | ||
US225056A (en) * | 1880-03-02 | Henry humphreville | ||
US10141A (en) * | 1853-10-18 | Improved life-preserving seat | ||
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
EP0989982B1 (en) | 1997-06-21 | 2005-08-17 | Roche Diagnostics GmbH | Barbituric acid derivatives with antimetastatic and antitumor activity |
US6265578B1 (en) | 1999-02-12 | 2001-07-24 | Hoffmann-La Roche Inc. | Pyrimidine-2,4,6-triones |
HN2000000137A (es) * | 1999-08-12 | 2001-02-02 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
AU2002210813A1 (en) * | 2000-10-26 | 2002-05-06 | Pfizer Products Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
US6841671B2 (en) | 2000-10-26 | 2005-01-11 | Pfizer Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
NZ524774A (en) | 2000-10-26 | 2004-09-24 | Pfizer Prod Inc | Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
WO2003091259A1 (en) | 2002-04-26 | 2003-11-06 | Pfizer Products Inc. | Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
NI200300045A (es) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
JP2005529895A (ja) | 2002-04-26 | 2005-10-06 | ファイザー・プロダクツ・インク | N置換へテロアリールオキシ−アリール−スピロ−ピリミジン−2,4,6−トリオンメタロプロテイナーゼ阻害剤 |
-
2003
- 2003-04-15 WO PCT/IB2003/001576 patent/WO2003091259A1/en active IP Right Grant
- 2003-04-15 BR BR0309281-0A patent/BR0309281A/pt not_active IP Right Cessation
- 2003-04-15 EP EP03715221A patent/EP1501834B1/en not_active Expired - Lifetime
- 2003-04-15 JP JP2003587817A patent/JP2005527598A/ja active Pending
- 2003-04-15 DE DE60301574T patent/DE60301574T2/de not_active Expired - Fee Related
- 2003-04-15 CA CA002483075A patent/CA2483075A1/en not_active Abandoned
- 2003-04-15 AT AT03715221T patent/ATE304015T1/de not_active IP Right Cessation
- 2003-04-15 ES ES03715221T patent/ES2247527T3/es not_active Expired - Lifetime
- 2003-04-15 AU AU2003219410A patent/AU2003219410A1/en not_active Abandoned
- 2003-04-15 MX MXPA04008563A patent/MXPA04008563A/es unknown
- 2003-04-21 TW TW092109244A patent/TW200306833A/zh unknown
- 2003-04-23 PE PE2003000403A patent/PE20040466A1/es not_active Application Discontinuation
- 2003-04-23 PA PA20038572201A patent/PA8572201A1/es unknown
- 2003-04-24 AR ARP030101422A patent/AR039661A1/es unknown
- 2003-04-24 UY UY27774A patent/UY27774A1/es not_active Application Discontinuation
- 2003-04-25 GT GT200300097A patent/GT200300097A/es unknown
- 2003-04-25 US US10/423,671 patent/US6916807B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2003091259A1 (en) | 2003-11-06 |
BR0309281A (pt) | 2005-02-22 |
PA8572201A1 (es) | 2004-03-10 |
EP1501834A1 (en) | 2005-02-02 |
GT200300097A (es) | 2004-06-15 |
AR039661A1 (es) | 2005-03-02 |
EP1501834B1 (en) | 2005-09-07 |
PE20040466A1 (es) | 2004-07-24 |
DE60301574D1 (de) | 2005-10-13 |
TW200306833A (en) | 2003-12-01 |
MXPA04008563A (es) | 2004-12-06 |
US20030225056A1 (en) | 2003-12-04 |
JP2005527598A (ja) | 2005-09-15 |
US6916807B2 (en) | 2005-07-12 |
AU2003219410A1 (en) | 2003-11-10 |
CA2483075A1 (en) | 2003-11-06 |
DE60301574T2 (de) | 2006-01-12 |
ATE304015T1 (de) | 2005-09-15 |
WO2003091259A8 (en) | 2004-02-12 |
AU2003219410A8 (en) | 2003-11-10 |
UY27774A1 (es) | 2003-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2247527T3 (es) | Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona. | |
ES2509820T3 (es) | Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer | |
AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
ECSP099395A (es) | Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico | |
CR9783A (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
AR049784A1 (es) | Derivados sustituidos de morfolina y tiomorfolina | |
AR050266A1 (es) | Derivados de bencil-triazolona como inhibidores no nucleosidos de transcriptasa inversa | |
ATE508747T1 (de) | C-kit kinase-hemmer | |
CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
ECSP066695A (es) | Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1 | |
CO6300865A2 (es) | Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
NI200600279A (es) | Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica | |
AR055635A1 (es) | Uso de sulfonanilidas como herbicidas | |
AR061548A1 (es) | 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii. | |
CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
CO5640118A2 (es) | 5,7-diaminopirazol[4,3-d]piridinas utiles en el tratamiento de la hipertension | |
AR067327A1 (es) | Derivados de piperidina / piperazina | |
CO5650164A2 (es) | Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
UY28141A1 (es) | Nuevos derivados de piridazin-3(2h)-ona | |
CO6251247A2 (es) | Imidazoquinolinas con propiedades inmuno-moduladoras | |
CO5650253A2 (es) | Piperazina con grupo fenilo or-sustituido y su uso como inhibidores de glyt1 | |
CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
AR072224A1 (es) | Derivados de pirimidona sustituidos | |
SV2009003152A (es) | Derivados novedosos de aminopiridina que tiene accion inhibidora selectiva sobre aurora a | |
ES2436020T3 (es) | Derivados de sulfonamida sustituidos |